CAJ | 학술논문

背景与目的：K-ras基因突变是抗表皮生长因子受体(epidermal growth factor receptor， EGFR)靶向治疗的重要负性预测因子。本研究拟对结直肠癌原发灶与转移灶中K-ras基因状态的一致性进行比较，以探讨目前临床K-ras检测的科学性与严谨性。方法：收集复旦大学附属肿瘤医院手术切除的结直肠癌原发灶及转移灶石蜡包埋组织76对，提取DNA，经过PCR扩增后，对产物进行基因序列分析，检测结直肠癌中K-ras基因外显子2基因序列。结果：76例患者中有15例结直肠癌原发灶与转移灶的K-ras基因突变情况不一致。76例结直肠癌原发灶有31例发生突变，突变率为40.8%，其中第13号密码子突变16例，第12号密码子突变15例；76例结直肠癌转移灶有31例发生突变，突变率为40.8%，其中第13号密码子突变15例，第12号密码子突变16例。结论：结直肠癌原发灶和转移灶中K-ras基因状态并不一致，且存在19.7%的表达差异率，提示通过检测原发灶K-ras基因表达状态来确定针对转移灶的西妥昔单克隆抗体药物选择存在不严谨性，需要进一步完善。
배경여목적：K-ras기인돌변시항표피생장인자수체(epidermal growth factor receptor， EGFR)파향치료적중요부성예측인자。본연구의대결직장암원발조여전이조중K-ras기인상태적일치성진행비교，이탐토목전림상K-ras검측적과학성여엄근성。방법：수집복단대학부속종류의원수술절제적결직장암원발조급전이조석사포매조직76대，제취DNA，경과PCR확증후，대산물진행기인서렬분석，검측결직장암중K-ras기인외현자2기인서렬。결과：76례환자중유15례결직장암원발조여전이조적K-ras기인돌변정황불일치。76례결직장암원발조유31례발생돌변，돌변솔위40.8%，기중제13호밀마자돌변16례，제12호밀마자돌변15례；76례결직장암전이조유31례발생돌변，돌변솔위40.8%，기중제13호밀마자돌변15례，제12호밀마자돌변16례。결론：결직장암원발조화전이조중K-ras기인상태병불일치，차존재19.7%적표체차이솔，제시통과검측원발조K-ras기인표체상태래학정침대전이조적서타석단극륭항체약물선택존재불엄근성，수요진일보완선。
Background and purpose:Metastatic colorectal cancer (mCRC) patients with K-ras mutation won’t benefit in the anti-epidermal growth factor receptor (EGFR) treatments. Thus K-ras mutation analysis is mandatory before this treatment. There is controversy that K-ras mutation analysis should be performed on primaries or related metastases. The aim of our study was to evaluate the concordance of K-ras status between primary and related metastases tumors, thus investigate the validity and rigorousness of clinical K-ras testing. Methods:Seventy-six patients with confirmed mCRC treated in Fudan University Shanghai Cancer Center were enrolled. After DNA extraction and PCR amplification, tumor specimens with paired primary tumors and related metastatic sites were put into sequencing analysis. And the K-ras mutation status in exon 2 was assessed. Results: K-ras mutation was detected in 31 out of 76 primary tumours (40.8%) and also 40.8%of the metastatic sites. But discordance was found between primary tumor and metastasis in 15 cases (19.7%):8 primary tumors had a K-ras mutation with a wild-type metastasis, meanwhile 7 primary tumors were wild type with a K-ras-mutated metastasis. Conclusion:Our study indicated that quite a few mCRC cases have different K-ras status between primary tumors and related metastatic sites, and it’s not very rigorous to choose the anti-EGFR treatments merely according to the primary tumor-K-ras mutation.Further study and consultation are needed on this problem.